News Releases
Fibrocell Science, Inc. to Present at the 2010 Global Hunter Securities Healthcare Conference
EXTON, Pa., August 11, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, Chairman and Chief Executive Officer, will present at the 2010 Global Hunter Securities Healthcare Conference at the Southern California Investor Conference onRead more
Fibrocell Science, Inc. Submits CSR to U.S. Food and Drug Administration for Phase II/III Trial of Azficel-T in Acne Scarring
Further Study Analysis in CSR Confirms Topline Results from Clinical Trial EXTON, Pa., August 9, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study ofRead more
Fibrocell Science, Inc. Announces Addition of Dr. George J. Korkos to Board of Directors
EXTON, Pa., July 20, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that George J. Korkos, M.D., D.D.S., F.A.C.S., has been appointed to its board of directors. Dr. Korkos currently serves as President of both Plastic SurgeryRead more
Fibrocell Science, Inc. Completes Enrollment and First Treatment Visits for Histology Study of azficel-T
EXTON, Pa., July 08, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currentlyRead more
Fibrocell Science, Inc. Appoints Advisors with Expertise in Periodontal/ Regenerative Dentistry and Burn Care
- Company Continues Evaluation of Broad Use of Proprietary Autologous Cell Therapy – EXTON, Pa., June 24, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the appointments of Nicolas Elian, D.D.S.; William K. Boss, M.D.; and DanielRead more
Follow Us
